Subtopic Deep Dive

BET Bromodomain Inhibitors
Research Guide

What is BET Bromodomain Inhibitors?

BET Bromodomain Inhibitors are small molecules that selectively bind and inhibit the bromodomains of BET family proteins (BRD2, BRD3, BRD4, BRDT) to disrupt their recognition of acetylated histones and transcriptional regulation.

Researchers developed these inhibitors starting with JQ1, which targets c-Myc-driven cancers (Delmore et al., 2011, 2794 citations). Structural studies mapped bromodomain binding pockets across 61 human bromodomains (Filippakopoulos et al., 2012, 1704 citations). PROTAC-based degraders like ARV-825 hijack cereblon to degrade BRD4 (Lü et al., 2015, 1096 citations; Zengerle et al., 2015, 994 citations).

Curated Papers

Key Challenges

Why It Matters

BET inhibitors suppress MYC expression in multiple myeloma (Delmore et al., 2011) and Burkitt lymphoma (Mertz et al., 2011). They show efficacy in castration-resistant prostate cancer by downregulating androgen receptor signaling (Asangani et al., 2014). PROTACs enable complete BRD4 degradation for superior anti-tumor effects over occupancy-based inhibition (Békés et al., 2022; Lü et al., 2015). Clinical trials target epigenetic dysregulation in solid tumors and inflammation (Cheng et al., 2019).

Key Research Challenges

Intra-BET selectivity

Pan-BET inhibitors like JQ1 lack selectivity among BRD2/3/4, causing off-target effects. Achieving degradation of specific BET paralogs remains difficult (Zengerle et al., 2015). Structural analysis reveals conserved binding pockets (Filippakopoulos et al., 2012).

Resistance mechanisms

Cancer cells develop resistance via MYC amplification or alternative epigenetic readers. Prolonged treatment reduces efficacy in prostate cancer models (Asangani et al., 2014). Combination therapies are underexplored (Cheng et al., 2019).

PROTAC optimization

Designing cell-permeable heterobifunctional degraders with optimal linker length for cereblon recruitment is challenging. BRD4 degraders show promise but require refined pharmacokinetics (Lü et al., 2015; Békés et al., 2022).

Essential Papers

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux et al. · 2011 · Cell · 2.8K citations

PROTAC targeted protein degraders: the past is prologue

Miklós Békés, David R. Langley, Craig M. Crews · 2022 · Nature Reviews Drug Discovery · 2.7K citations

Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family

P. Filippakopoulos, S. Picaud, Maria Mangos et al. · 2012 · Cell · 1.7K citations

Epigenetic protein families: a new frontier for drug discovery

C.H. Arrowsmith, C. Bountra, Paul V. Fish et al. · 2012 · Nature Reviews Drug Discovery · 1.3K citations

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

Jing Lü, Yimin Qian, Martha Altieri et al. · 2015 · Chemistry & Biology · 1.1K citations

Targeting MYC dependence in cancer by inhibiting BET bromodomains

Jennifer A. Mertz, Andrew R. Conery, Barbara M. Bryant et al. · 2011 · Proceedings of the National Academy of Sciences · 1.1K citations

The MYC transcription factor is a master regulator of diverse cellular functions and has been long considered a compelling therapeutic target because of its role in a range of human malignancies. H...

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

Yuan Cheng, He Cai, Manni Wang et al. · 2019 · Signal Transduction and Targeted Therapy · 1.0K citations

Reading Guide

Foundational Papers

Read Delmore et al. (2011) first for therapeutic validation in myeloma (2794 citations), then Filippakopoulos et al. (2012) for domain structures (1704 citations), followed by Mertz et al. (2011) for MYC mechanism.

Recent Advances

Study Békés et al. (2022) for PROTAC evolution (2669 citations) and Zengerle et al. (2015) for selective BRD4 degradation (994 citations).

Core Methods

Bromodomain crystal structures guide inhibitor design (Filippakopoulos et al., 2012); PROTAC ternary complex optimization via cereblon recruitment (Lü et al., 2015); dose-response assays measure occupancy vs. degradation (Zengerle et al., 2015).

How PapersFlow Helps You Research BET Bromodomain Inhibitors

Discover & Search

Research Agent uses citationGraph on Delmore et al. (2011) to map 2794 citing papers linking BET inhibition to PROTACs, then findSimilarPapers reveals degraders like ARV-825 (Lü et al., 2015). exaSearch queries 'BET PROTAC clinical trials post-2020' for trial updates beyond listed papers.

Analyze & Verify

Analysis Agent runs readPaperContent on Zengerle et al. (2015) to extract dBET6 degradation kinetics, then runPythonAnalysis with pandas fits dose-response curves from supplementary data. verifyResponse (CoVe) cross-checks claims against Filippakopoulos et al. (2012) structures; GRADE scores evidence as A-level for BRD4 selectivity.

Synthesize & Write

Synthesis Agent detects gaps in resistance mechanisms by flagging underexplored MYC rebound post-BRD4 degradation (Delmore vs. Asangani papers). Writing Agent uses latexEditText to draft inhibitor comparison tables, latexSyncCitations for 10+ references, and latexCompile for publication-ready review; exportMermaid diagrams PROTAC mechanism.

Use Cases

"Extract IC50 values for JQ1 and dBET6 from BET inhibitor papers and plot dose-response curves"

Research Agent → searchPapers('JQ1 dBET6 IC50') → Analysis Agent → readPaperContent(Zengerle 2015) + runPythonAnalysis(pandas/matplotlib curve fitting) → matplotlib plot of degradation efficiency vs. concentration.

"Write a LaTeX methods section comparing BET inhibitor vs PROTAC mechanisms with citations"

Synthesis Agent → gap detection(Delmore 2011 + Lü 2015) → Writing Agent → latexEditText(structure diagram) → latexSyncCitations(10 papers) → latexCompile → PDF with embedded PROTAC schematic.

"Find GitHub repos with BRD4 PROTAC simulation code from recent papers"

Research Agent → searchPapers('BRD4 PROTAC simulation code') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Verified MD simulation scripts for cereblon-BRD4 docking.

Automated Workflows

Deep Research workflow scans 50+ citing papers to Delmore et al. (2011) via citationGraph → structures systematic review of BET inhibitors in 12 cancer types with GRADE evidence tables. DeepScan applies 7-step analysis to Lü et al. (2015) PROTAC design, verifying linker optimization with runPythonAnalysis. Theorizer generates hypotheses on BRD4/BRD2 paralog compensation from Filippakopoulos et al. (2012) structures + resistance data.

Try Doxa for BET Bromodomain Inhibitors Research

Frequently Asked Questions

What defines BET Bromodomain Inhibitors?

Small molecules binding acetyl-lysine pockets in BRD2/3/4/BRDT bromodomains to block histone association and transcription (Filippakopoulos et al., 2012).

What are key methods for BET targeting?

Competitive inhibitors like JQ1 occupy bromodomains (Delmore et al., 2011); PROTACs like dBET6 recruit cereblon for ubiquitination/degradation (Zengerle et al., 2015; Lü et al., 2015).

What are seminal papers?

Delmore et al. (2011, Cell, 2794 citations) showed c-Myc suppression; Filippakopoulos et al. (2012, Cell, 1704 citations) provided bromodomain structures; Mertz et al. (2011, PNAS, 1095 citations) validated MYC targeting.

What open problems exist?

Intra-BET selectivity, acquired resistance via MYC rebound, and PROTAC oral bioavailability for clinical translation (Asangani et al., 2014; Békés et al., 2022).